Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
KROS
Strong SellSinkerKeros Therapeutics, Inc. · Healthcare · United States · $219M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Keros Therapeutics, Inc. is a U.S. clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for musculoskeletal and rare blood disorders. The company's innovative approach targets the transforming growth factor-beta (TGF-ß) superfamily, aiming to create first-in-class treatments for areas with significant unmet medical needs. Its competitive strategy is centered on a deep understanding of disease biology and a proprietary drug discovery platform to address specific, high-value indications.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0.2M | 3.5M | 244.1M | 3920.3% | 15.0M | 15.6M | 13.7M | -76.3% |
| EPS | -2.52 | -4.15 | -5.20 | -10.25 | 2.34 | — | -3.22 | -5.22 | -6.62 | — |
| Shares | — | 27.5M | 31.8M | 19.8M | 19.5M | -29.0% | 19.8M | — | — | — |
| Debt | — | 13.3M | 14.4M | 18.9M | 16.9M | 8.4% | 15.7M | — | — | — |
| Equity | — | 277.4M | 332.2M | 571.6M | 303.1M | 3.0% | — | — | — | — |
| Op CF | — | -70.1M | -124.5M | -160.9M | 107.5M | — | -48.0M | — | — | — |
| Inv CF | — | -1.2M | -2.5M | -1.9M | -1.6M | — | — | — | — | — |
| Fin CF | — | 120.3M | 179.0M | 391.8M | -378.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KROS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KROS | Keros Therapeutics, Inc.(you) | $219M | 15 | Strong Sell |
| VYGR | Voyager Therapeutics, Inc. | $218M | 14 | Strong Sell |
| PEPG | PepGen Inc. | $213M | 14 | Strong Sell |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $233M | 15 | Strong Sell |
| CHRS | Coherus Oncology, Inc. | $218M | 13 | Strong Sell |
| ABOS | Acumen Pharmaceuticals, Inc. | $211M | 13 | Strong Sell |
| CUE | Cue Biopharma, Inc. | $203M | 17 | Strong Sell |
| ELDN | Eledon Pharmaceuticals, Inc. | $260M | 15 | Strong Sell |
| KRRO | Korro Bio, Inc. | $190M | 16 | Strong Sell |
| PYXS | Pyxis Oncology, Inc. | $269M | 15 | Strong Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.3%